{"id":"https://openalex.org/W1509282900","doi":null,"title":"Monoclonal antibody: the corner stone of modern biotherapeutics.","display_name":"Monoclonal antibody: the corner stone of modern biotherapeutics.","publication_year":2012,"publication_date":"2012-10-01","ids":{"openalex":"https://openalex.org/W1509282900","mag":"1509282900","pmid":"https://pubmed.ncbi.nlm.nih.gov/23289138"},"language":"en","primary_location":{"id":"pmid:23289138","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23289138","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Yao xue xue bao = Acta pharmaceutica Sinica","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102026123","display_name":"Zhinan Xia","orcid":"https://orcid.org/0000-0003-0423-4405","observed_orcids":["https://orcid.org/0000-0003-0423-4405"]},"institutions":[{"id":"https://openalex.org/I4210122397","display_name":"Synageva BioPharma (United States)","ror":"https://ror.org/0310bxj37","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122397"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhi-nan Xia","raw_affiliation_strings":["R&D Synageva Biopharma Corporation, Lexington, MA 02421, USA. xia8894@yahoo.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Synageva Biopharma Corporation, Lexington, MA 02421, USA. xia8894@yahoo.com","institution_ids":["https://openalex.org/I4210122397"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070699990","display_name":"Xue-ting Cai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xue-ting Cai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Peng Cao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peng Cao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.07150525,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"47","issue":"10","first_page":"1275","last_page":"80"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.989300012588501,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.989300012588501,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.007000000216066837,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/therapeutic-monoclonal-antibodies","display_name":"therapeutic monoclonal antibodies","score":0.9150000214576721},{"id":"https://openalex.org/keywords/biosimilars","display_name":"biosimilars","score":0.9769999980926514},{"id":"https://openalex.org/keywords/biopharmaceuticals","display_name":"biopharmaceuticals","score":0.7120000123977661},{"id":"https://openalex.org/keywords/biosimilar-approval","display_name":"biosimilar approval","score":0.7170000076293945},{"id":"https://openalex.org/keywords/regulatory-framework","display_name":"regulatory framework","score":0.8479999899864197},{"id":"https://openalex.org/keywords/patent-expiration","display_name":"patent expiry","score":0.48100000619888306},{"id":"https://openalex.org/keywords/emerging-markets","display_name":"emerging markets","score":0.5099999904632568}],"concepts":[{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.9932944774627686},{"id":"https://openalex.org/C2781047461","wikidata":"https://www.wikidata.org/wiki/Q679692","display_name":"Biopharmaceutical","level":2,"score":0.7683691382408142},{"id":"https://openalex.org/C3018890749","wikidata":"https://www.wikidata.org/wiki/Q204711","display_name":"Food and drug administration","level":2,"score":0.7328401803970337},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5644183158874512},{"id":"https://openalex.org/C2992293740","wikidata":"https://www.wikidata.org/wiki/Q4781752","display_name":"Drug approval","level":3,"score":0.5613770484924316},{"id":"https://openalex.org/C2910001868","wikidata":"https://www.wikidata.org/wiki/Q458","display_name":"European union","level":2,"score":0.5441398024559021},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49636727571487427},{"id":"https://openalex.org/C108170787","wikidata":"https://www.wikidata.org/wiki/Q3951828","display_name":"Agency (philosophy)","level":2,"score":0.45862171053886414},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4231339693069458},{"id":"https://openalex.org/C2910862244","wikidata":"https://www.wikidata.org/wiki/Q7240896","display_name":"Drug prices","level":2,"score":0.4213460385799408},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35498619079589844},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.3357304036617279},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.2162243127822876},{"id":"https://openalex.org/C155202549","wikidata":"https://www.wikidata.org/wiki/Q178803","display_name":"International trade","level":1,"score":0.1979849636554718},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.15521946549415588},{"id":"https://openalex.org/C100001284","wikidata":"https://www.wikidata.org/wiki/Q2248246","display_name":"Public economics","level":1,"score":0.12257930636405945},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.10855928063392639},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.09347820281982422},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C111472728","wikidata":"https://www.wikidata.org/wiki/Q9471","display_name":"Epistemology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005062","descriptor_name":"European Union","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":3,"locations":[{"id":"pmid:23289138","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23289138","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Yao xue xue bao = Acta pharmaceutica Sinica","raw_type":"Journal Article"},{"id":"mag:1509282900","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23289138","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null},{"id":"mag:3148082393","doi":null,"is_oa":false,"landing_page_url":"http://www.cqvip.com/QK/90148X/201210/43582377.html","pdf_url":null,"source":{"id":"https://openalex.org/S2753569916","display_name":"Yaoxue xuebao","issn_l":"0513-4870","issn":["0513-4870"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"\u836f\u5b66\u5b66\u62a5","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.5683000087738037,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7162059970","https://openalex.org/W2187288518","https://openalex.org/W2794235981","https://openalex.org/W2893754264","https://openalex.org/W2094052190","https://openalex.org/W3145072683","https://openalex.org/W4240681567","https://openalex.org/W2333679441","https://openalex.org/W1967229902","https://openalex.org/W2581362677"],"abstract_inverted_index":{"Worldwide":[0],"sales":[1],"of":[2,62,107,115],"biologic":[3,108],"drugs":[4],"exceeded":[5],"100":[6],"billion":[7],"USD":[8],"in":[9,74,131],"2011.":[10],"About":[11],"32%":[12],"is":[13,30,103],"from":[14],"therapeutic":[15],"monoclonal":[16],"antibody":[17],"(mAb).":[18],"With":[19],"many":[20],"blockbuster":[21],"biopharmaceutical":[22],"patents":[23],"expiring":[24],"over":[25],"the":[26,38,59,75,91,104,113,119],"next":[27],"decade,":[28],"there":[29],"a":[31,69,98],"great":[32],"opportunity":[33],"for":[34,58,77,83],"biosimilar":[35,63,84,144],"to":[36,142],"enter":[37],"worldwide":[39],"especially":[40],"emerging":[41],"market.":[42],"Both":[43],"European":[44,124],"Medicines":[45],"Agency":[46],"(EMA)":[47],"and":[48,50,90,123,129],"Food":[49],"Drug":[51],"Administration":[52],"(FDA)":[53],"have":[54],"introduced":[55],"regulatory":[56],"frameworks":[57],"potential":[60],"approval":[61,82],"mAb":[64,85,102,110,128],"therapeutics.":[65],"Rather":[66],"than":[67],"providing":[68],"highly":[70],"abbreviated":[71],"path,":[72],"as":[73],"case":[76],"small":[78],"molecule":[79],"chemical":[80],"drug,":[81],"will":[86,93,111,135,146],"require":[87],"clinical":[88],"trial":[89],"details":[92],"be":[94,112,136,147],"very":[95],"much":[96],"on":[97,140],"case-by-case":[99],"basis.":[100],"Since":[101],"dominant":[105],"category":[106],"drugs,":[109],"focus":[114],"this":[116],"review.":[117],"First,":[118],"United":[120],"States":[121],"(US)":[122],"Union":[125],"(EU)":[126],"approved":[127],"those":[130],"phase":[132],"3":[133],"trials":[134],"reviewed,":[137],"then":[138],"strategies":[139],"how":[141],"win":[143],"competition":[145],"reviewed.":[148]},"counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}